The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis ...
In people living with HIV, each additional year of integrase inhibitor use is associated with higher odds of severe liver ...
Opportunistic CT mapping shows lower bone density with older age across the pelvis, sacrum, lower spine, and proximal femur, ...
A large review suggests that chatbots may trigger delusions and/or fuel psychosis, in some of the first systematic clinical ...
People who undergo a carbohydrate challenge have smaller postprandial glucose excursions when they eat with a romantic ...
Research presented at ASRM 2026 shows that relugolix combination therapy, used for fibroids and endometriosis, shows strong ...
The BTK inhibitor remibrutnib reduces relapse rates and MRI lesion activity compared with teriflunomide in relapsing MS, ...
In two UK surveys, childhood betrayal trauma is linked to shame and dissociation, both of which are linked to greater fear of ...
In patients with inflammatory bowel disease and concurrent primary sclerosing cholangitis, advanced therapies appear modestly ...
The number of coronary vessels treated in acute coronary syndrome varies widely between operators — far more than patient ...
Naronapride, an investigational prokinetic, leads to greater improvements in gastroparesis symptoms than placebo when administered at 20 and 40 mg three times daily, a phase 2 trial shows.
Adding emotion regulation training to weight-loss treatment is associated with less BMI regain after the intervention ends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results